학술논문
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production.
Document Type
Article
Author
Source
Subject
*RIBONUCLEOSIDE diphosphate reductase
*GLIOBLASTOMA multiforme
*URIDINE
*BIOLOGICAL evolution
*METHYLGUANINE
*AUTOMATIC gain control
*NOTCH signaling pathway
*
*
*
*
*
*
Language
ISSN
2375-2548
Abstract
The article discusses about plasticity-induced adaptation during standard-of-care chemotherapy temozolomide (TMZ). It further discusses about in vivo single-cell RNA sequencing in patient-derived xenograft (PDX) tumors of glioblastoma (GBM) before, during, and after therapy; dGTP and dCTP production vital for DNA damage response during TMZ therapy; and strong correlations between ribonucleotide reductase regulatory subunit M2 (RRM2) and deoxyguanosine triphosphate (dGTP).